Solid growth, improved profitability and lower leverage


Grifols reported revenue of EUR 2,040 million in the third quarter of 2026, up 8.4% year over year on a constant-currency basis, primarily driven by growth in the Biopharma business.

Press Release

Grifols increases revenue by 8.4% to EUR 2,040 million and grows net profit by 28% to EUR 162m in Q3’26

Read Release

Webcast

Q3’2026 Earnings Results on November 2, 2026, at 5:35pm CET. Webcast scheduled at 6:30pm CET

Access webcast

Image Gallery

Get a set of ready-to-use images

Download

9M 2026 Key figures and metrics

Q3 2026 delivery builds on YTD strong performance.

Revenue

€5,614m

+4.6% cc1

Group Profit

€390m

+28.4%

Adjusted EBITDA

€1,392m

+5.0% cc1

Adjusted EBITDA margin

24.8%

+30 bps

Free Cash Flow pre-M&A

€298m

+€110m

Leverage ratio2

3.98x

1Constant Currency.

2 Leverage ratio defined as per the Credit Agreement.

“We are making progress on strategic initiatives that will strengthen our global plasma sourcing model and improve our cost structure over time. Our focus remains on delivering our commitments and building a more competitive Grifols for the long term.”

Nacho Abia Chief Executive Officer

Results Q&A

The results reflect solid growth, improved profitability and strong cash generation. Revenue increased 8.4% at constant currency in the quarter, net profit grew 27.9%, and the adjusted EBITDA margin reached 26.4%.

Biopharma remains Grifols’ primary growth driver, with revenue increasing 10.3% at constant currency in the third quarter. The immunoglobulin franchise continued to perform strongly, with revenue up 11.3% at constant currency.

Profitability continues to improve, supported by volume growth, a higher contribution from a favorable product mix and continued cost discipline. Adjusted EBITDA reached EUR 538 million in the third quarter, with a margin of 26.4%.

Free cash flow pre-M&A reached EUR 208 million in the third quarter and EUR 298 million in the first nine months of the year. Net leverage declined further to 3.98x, compared with 4.2x in the same period of 2025.

Yes. Grifols remains on track to deliver its full-year 2026 guidance, supported by its performance in the first nine months of the year.

Grifols continues to diversify its global plasma network, with significant progress in Egypt. Grifols Egypt is on track to collect approximately one million liters of plasma in 2026 and is progressing toward its goal of collecting up to three million liters annually by 2029.

INVESTORS

Financial Results

Financial results published by the company.

Media Center

Downloadable resources for media professionals.